The progress of new discoveries must be celebrated
Retrenchment in industry has led to concerns about spread of ‘pharmacy deserts’ with limited access to medicines
Autolus hopes its less gruelling Car-T treatment for a type of leukaemia will allow it to compete with bigger rivals
Appetite will pick up as interest rates fall, but uneven distribution of funding and rewards looks set to persist
Regulatory go-ahead marks latest boost for drugmaker’s blockbuster anti-obesity franchise
Obesity treatment CagriSema misses goal of 25% reduction in body weight
Market will never be winner takes all given that different patients will have different requirements
Treatment for short bowel syndrome fails to win approval from US regulator
Boss David Epstein hopes to replicate his success at Seagen after $43bn sale last year
FTSE 100 group reportedly faces difficulties in selling drugs to Chinese hospitals
Deal with BC Partners aims to capitalise on rising demand for off-patent versions of complex drugs
Firm settles criminal investigation and former senior partner admits obstruction of justice
Funding for existing services would have helped more patients
Initial research has focused on obesity, but Ozempic, Wegovy and Mounjaro may potentially be used for addiction, heart disease and Alzheimer’s
Experts expect Trump regulators to be less hawkish on challenging proposed acquisitions in the sector
And quality in the small cap rally
Company veteran Iskra Reic moves to Shanghai after Leon Wang placed under investigation by authorities
Report by industry group finds MHRA’s ‘capacity and predictability’ is biggest factor deterring investment
Experts forecast Trump administration could usher in new era of mergers and acquisitions among drugmakers
Abingworth wants to pursue royalty-based partnerships with major pharma groups
This is a time for treating people as individuals rather than as members of a tribe
Radical former Democrat wants to take on Big Pharma — but his team is already arguing
Author recommends breaking ‘siloed’ work practices to spur life sciences sector and improve care
State-backed insurance programmes would fund drugs for obese patients without separate health conditions
Trump nominee's vaccine scepticism worries industry
